<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04925661</url>
  </required_header>
  <id_info>
    <org_study_id>HEC53856-RAD-102</org_study_id>
    <nct_id>NCT04925661</nct_id>
  </id_info>
  <brief_title>HEC53856 Phase Ib Study in Patients With Non-dialysis Renal Anemia</brief_title>
  <official_title>Phase Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HEC53856 Capsules in Patients With Non-dialysis Renal Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunshine Lake Pharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nicoya Therapeutics (Shanghai) Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sunshine Lake Pharma Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety, tolerability , pharmacokinetics and Preliminary Efficacy of HEC53856&#xD;
      Capsules in Patients With Non-dialysis Renal Anemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a MultiCenter, Randomized, Blinded, Active Drug and Placebo-controlled,&#xD;
      Dose-escalated Phase Ib Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics&#xD;
      and Preliminary Efficacy of HEC53856 Capsules in Patients With Non-dialysis Renal Anemia.&#xD;
      Each part participants will be randomly administrated for HEC53856 or placebo or roxadustat.&#xD;
&#xD;
      The study consisted of three study periods as follows:&#xD;
&#xD;
      Screening period: up to 2 weeks； Treatment period: 8 weeks； Post-Treatment Follow-Up period:&#xD;
      4 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 29, 2021</start_date>
  <completion_date type="Anticipated">May 10, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 26, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The positive drug is Masking and the placebo-controlled is open.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>Through study completion, an average of 12 weeks.</time_frame>
    <description>To assess the safety and tolerability of therapy by incidence of treatment-emergent adverse events after multiple doses of HEC53856 capsule</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>Day 1(Dosing) until Day 55 after single and multiple drug dosing.</time_frame>
    <description>Area under the concentration versus time curve (AUC) from time zero to the time of the last quantifiable concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>Day 1(Dosing) until Day 55 after single and multiple drug dosing.</time_frame>
    <description>Maximum observed plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Day 1(Dosing) until Day 55 after single and multiple drug dosing.</time_frame>
    <description>Time of the maximum observed plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T½</measure>
    <time_frame>Day 1(Dosing) until Day 55 after single and multiple drug dosing.</time_frame>
    <description>Apparent terminal elimination half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F</measure>
    <time_frame>Day 1(Dosing) until Day 55 after single and multiple drug dosing.</time_frame>
    <description>Apparent volume of distribution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in mean hemoglobin</measure>
    <time_frame>week 10</time_frame>
    <description>Changes in mean hemoglobin (Hb) relative to baseline during weeks 8 and 10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin response</measure>
    <time_frame>week 10</time_frame>
    <description>Percentage of subjects who met the hemoglobin response after dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>E-AUC0-t</measure>
    <time_frame>Day 1(Dosing) until Day 55 after single and multiple drug dosing.</time_frame>
    <description>Area under the EPO concentration versus time curve (AUC) from time zero to the time of the last quantifiable concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emax</measure>
    <time_frame>Day 1(Dosing) until Day 55 after single and multiple drug dosing.</time_frame>
    <description>Maximum observed EPO concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>E-Tmax</measure>
    <time_frame>Day 1(Dosing) until Day 55 after single and multiple drug dosing.</time_frame>
    <description>Time of the maximum observed EPO concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum lipid</measure>
    <time_frame>Up to Day 55</time_frame>
    <description>Changes in Serum lipid relative to baseline at weeks 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Indicators of iron</measure>
    <time_frame>Up to Day 55</time_frame>
    <description>Changes in the Indicators of iron relative to baseline at weeks 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High-sensitivity C-reactive protein</measure>
    <time_frame>Up to Day 55</time_frame>
    <description>Changes in the High-sensitivity C-reactive protein relative to baseline at weeks 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reticulocytes</measure>
    <time_frame>Up to Day 85</time_frame>
    <description>Changes in the mean Reticulocytes relative to baseline after doses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VEGF</measure>
    <time_frame>Up to Day 55</time_frame>
    <description>Changes in the VEGF relative to baseline after doses.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Chronic Kidney Diseases</condition>
  <condition>Renal Anemia</condition>
  <arm_group>
    <arm_group_label>HEC53856</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: HEC53856 TIW dosing, capsule There will be a total of 3 dose cohorts: 100mg, 150mg, 200 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Roxadustat</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: roxadustat TIW dosing There will be only one cohort: 70mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug: placebo TIW dosing, capsule There will be a total of 3 dose cohorts: 100mg, 150mg, 200 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HEC53856</intervention_name>
    <description>Either dose of HEC53856 will be administered after fasting .</description>
    <arm_group_label>HEC53856</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Roxadustat</intervention_name>
    <description>Roxadustat will be administered after fasting .</description>
    <arm_group_label>Roxadustat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Either dose of placebo will be administered after fasting .</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients who agree to participate in this clinical trial and sign an informed consent&#xD;
             form;&#xD;
&#xD;
          2. Age 18~65 years old; Weight 40~90Kg, including critical value;&#xD;
&#xD;
          3. Glomerular filtration rate (eGFR) calculated by CKD-EPI formula 15mL/min/1.73 m^2 &lt; or&#xD;
             = eGFR &lt; 60 mL/min/1.73 m^2 diagnosed chronic kidney disease patients who have not&#xD;
             received dialysis;&#xD;
&#xD;
          4. The hemoglobin values obtained during the last two screening periods at least 6 days&#xD;
             apart must be &gt; or = 8.0 g/dL and &lt;10 g/dL.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Existence of diseases or conditions other than nephropathy that may cause anemia,&#xD;
             including but not limited to 1) blood system diseases, such as thalassemia, aplastic&#xD;
             anemia, hemolytic anemia, multiple myeloma, myelodysplastic syndrome, etc.; 2) may&#xD;
             affect red blood cells The resulting autoimmune diseases, such as systemic lupus&#xD;
             erythematosus, rheumatoid arthritis, etc.; 3) Bleeding diseases, such as&#xD;
             gastrointestinal bleeding, obstetrics and gynecology bleeding diseases, etc.; 4)&#xD;
             Elective surgery expected during the study period;&#xD;
&#xD;
          2. Drugs used to treat anemia within 8 weeks before the first administration, including&#xD;
             but not limited to erythropoiesis stimulators (ESAs) and their derivatives, hypoxia&#xD;
             inducible factor prolyl hydroxylase inhibitors (HIF-PHI), androgens And anabolic&#xD;
             hormone drugs, intravenous iron, Chinese patent medicine, Chinese herbal medicine,&#xD;
             etc. (Can accept patients who have used a fixed dose of oral iron within 4 weeks&#xD;
             before screening, and continue to take it during the screening period and the first 4&#xD;
             weeks after starting to take the test drug The fixed dose remains unchanged.);&#xD;
&#xD;
          3. Those who have received blood transfusion within 3 months before the first&#xD;
             administration;&#xD;
&#xD;
          4. Folic acid &lt;6.8nmol/L (3ng/ml) and (or) VitB12&lt;74pmol/L (100ng/ml) during the&#xD;
             screening period;&#xD;
&#xD;
          5. Clinically significant chronic liver and gallbladder disease, or obvious abnormal&#xD;
             liver function: ALT&gt;3×ULN and/or AST&gt;3×ULN, or total bilirubin&gt;1.5×ULN;&#xD;
&#xD;
          6. Serum albumin &lt;3 g/dL;&#xD;
&#xD;
          7. The mean systolic blood pressure &gt; or = 160 mmHg and/or the diastolic blood pressure &gt;&#xD;
             or = 100 mmHg of the two blood pressure measurements at least one hour apart during&#xD;
             the screening period;&#xD;
&#xD;
          8. Suffering from uncontrollable or symptomatic secondary hyperparathyroidism, plasma&#xD;
             iPTH &gt; 500pg/ml;&#xD;
&#xD;
          9. A history of acute or chronic pancreatitis, or acute or chronic pancreatitis at the&#xD;
             time of screening, or blood amylase &gt; or = 3×ULN;&#xD;
&#xD;
         10. History of malignant tumors within 5 years (except for cured skin basal cell carcinoma&#xD;
             and cervical carcinoma in situ), or current assessment of potential malignant tumors;&#xD;
&#xD;
         11. Patients with acute coronary syndrome, stroke ( except for lacunar infarction )or&#xD;
             thromboembolic diseases (such as deep vein thrombosis or pulmonary embolism) occurred&#xD;
             in the 6 months before screening;&#xD;
&#xD;
         12. New York Society of Cardiology, grade III or IV congestive heart failure, or severe&#xD;
             arrhythmia, including but not limited to atrial fibrillation, III degree&#xD;
             atrioventricular block, etc.;&#xD;
&#xD;
         13. AIDS antibody, Treponema pallidum antibody, hepatitis B surface antigen or hepatitis C&#xD;
             antibody positive for any of them;&#xD;
&#xD;
         14. People with a history of severe allergic disease or drug allergy, or those who are&#xD;
             allergic to experimental drugs or their excipients;&#xD;
&#xD;
         15. Patients with clinically severe infections who are receiving systemic antibiotic&#xD;
             treatment;&#xD;
&#xD;
         16. Those who have started dialysis or plan to start dialysis treatment within 6 months;&#xD;
&#xD;
         17. Anyone who has participated in or plans to participate in organ transplantation within&#xD;
             6 months;&#xD;
&#xD;
         18. Patients with hemoglobinosis, polycystic kidney disease, or no kidney;&#xD;
&#xD;
         19. Women during pregnancy or lactation, or fertile men and women who refuse to take&#xD;
             effective contraceptive measures voluntarily from the beginning of screening to 4&#xD;
             weeks after the administration of the last trial drug;&#xD;
&#xD;
         20. Participated in other clinical trials within 3 months before screening (Definition of&#xD;
             participation: accepted trial drug or instrument);&#xD;
&#xD;
         21. The investigator believes that there are other factors that are not suitable for&#xD;
             participating in this trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The sixth Affiliated Hospital, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhejiang Provincal People's Hospital</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The People's Hospital of Guangxi Zhuang Autonmous Region</name>
      <address>
        <city>Nanning</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huashan Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruijin Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Xi'an Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xiamen University</name>
      <address>
        <city>Xiamen</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xinjiang Medical University</name>
      <address>
        <city>Ürümqi</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 30, 2021</study_first_submitted>
  <study_first_submitted_qc>June 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2021</study_first_posted>
  <last_update_submitted>June 21, 2021</last_update_submitted>
  <last_update_submitted_qc>June 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

